https://www.theedgemarkets.com/article/iris-announce-entry-new-shareholder-week

Caprice development 66mil shares 4th largest shareholder a few weeks ago is not even in the top 20 now. Poh and co sold out lol fyi Investgaogao

the same rent seekers are selling...parasites

Companies ought to shift emphasis from govt projects as these invariably have pitfalls to political whims

While you buy he sells. rogue

Major contractors ought to shift emphasis from govt projects due to unreliability

if it crosses 45 then next resistance 60 sen

there are investors hurting from the down draft in prices so some of you out there ought to cut them some slack and not ridicule the price action. It could be a naive investor’s lifesaving down the plug hole. You think it’s fun then suffer carrying the guilt of unintended consequences. You wont be the first nor the last with a guilty conscience. It’s bad karma.

oh well rampers and derampers here too

PP dependent on award timing which suggest to me it has been delayed a bit

Indeed

On September 28, shares in Semiconductor Manufacturing International Corporation (SMIC) plunged about 27% after the U.S. Commerce Department announced new export restrictions on China's biggest chipmaker. .

most of the impact has been accounted for already. So there is nothing new to this and it may have experienced some slight fall on official announcement. An old story

SMIC knew several months ahead it was to be blacklisted ...it is an old story

Don't trust KYY's calculations when deciding to buy stocks.

nikicheong..RHB research

Maintain BUY and MYR0.38 TP, 41% upside. 9M20 results are deemed
within expectations, potentially dragged by the anticipation of seasonally
weaker offshore marine services (OMS) segment in 4Q20F. 9M20 core
earnings improved 37% YoY, underpinned by better FPO numbers. Bumi
Armada’s risk-reward profile stays attractive, as its current 4x FY21F P/E
and 0.4x FY21F P/BV (-1.5SD from its 5-year mean) reflect an elevated
2.6x net gearing, as at 3Q20

KYY ..what a rogue

not cap 3 kepala ayam lol

Hi Guys does anyone have Maybank's latest valuation of Hartalega based on DCF method.. don't need the report just the price.

TTD1990 "The worst kind off ppl are the ones who make fun and laugh at others misery. Pls dont have children, because u will be raising pieces shit like urself."

Concur as there are some incorrigible retards in this forum

KYY starts of well then transforms into a con

it was a lockdown fear sell down ; any further lockdown would see economies crashing and the cost would exceed any benefit accrued. Best to target clusters.

being churned by interest

Gnath_77 astute!

I am concerned

1.33 bil PAT

mega buster earnings in a qtr

Mikecyc you could have made so much if you had gone long. I am pretty sure you did

KYY sold early, not a trustworthy fellow;starts with good intentions and transforms into a sneak

TG Singapore price ramped up 2.94 as we speak ( 8.90 on 3.04 conversion Sing to RM)

TG Singapore price ramped up 2.94 as we speak ( 8.90 on 3.04 conversion Sing to RM)

TG Singapore is up

HNWInvestor but if the cap fits you wear it

HNWInvestor of course not mate , nothing personal

yahooo!!!!

from a major supplier ...scurry off you trolls

cant meet demand in next 3 years that is a big statement

KUALA LUMPUR (Sept 15): The supply of the rubber gloves will not be able to meet the demand in the next three years, said Hartalega Holdings Bhd executive chairman Kuan Kam Hon.

Speaking to reporters at a press conference after the group’s annual general meeting today, Kuan said currently there is an enormous shortage of gloves due to the Covid-19 pandemic.

“Right now, there is an enormous shortage, so we (are) always short on gloves. So the system is compromising because there's not enough gloves. So we do not even know whether we have 120 billion more pieces of gloves in the next three years, do you think it's sufficient? I don't think it's sufficient.




READ MORE
“Glove dipping is a long process, the expansion transition period [for gloves] is at least three years, we are constantly expanding, and what is our glove (production) per annum? Maybe 20%, slightly more than the organic growth,” he said.

Kuan added: "To us, (this) is a big challenge because it is in relation to our capacity, in relation to what we produce, 20% is a lot more."

Supermax already higher than topglove... Marktcap Topglove 70 bil, Supermax 25 bil

but then that is what that makes it all interesting; profits

and all the experts have disappeared..from 1.9 safe buy etc etc...crap advice abounds in this forum. Few do number crunching ( DCF etc) and look at momentum. There are of course concerns when Investment Banks act in conflict of interest situations but to then have all these clowns pile on is a bigger joke

Boy I wish I had that much time disparaging a stock that I don't wish to buy.What a tangled web we weave

Mikecyc appears to have serious interest in buying glove stocks at some point as he seems preoccupied with it with incessant trolling.

NewToThis well done mate for being a gentleman unlike some of the crap trolls we get here.... Misery loves company

26 August to 10 Sept about turn in valuation.. suggest target at half the price
one can only conclude market manipulation knowing it postilion s as an Investment Bank,never mind the disclaimers

Macquarie has to be investigated

all these syndicate type comments lol

just hike ASP

Late stage trials for the vaccine being developed by AstraZeneca and Oxford University have been put on hold
A 'serious adverse event,' a possible reaction to the shot was reported in the UK
It's not clear what happened to the individual, but an adverse event is considered 'serious' if it requires hospitalization, is life-threatening or deadly
Stat News reported that the individual is expected to recover, but little else is known about their identity
It is not clear if regulators, AstraZeneca or Oxford called for the trial hold
The shot was dubbed the best hope for a vaccine by the WHO and is one of nine in phase three trials - the last tests before approval can be sought

Late stage trials for the vaccine being developed by AstraZeneca and Oxford University have been put on hold
A 'serious adverse event,' a possible reaction to the shot was reported in the UK
It's not clear what happened to the individual, but an adverse event is considered 'serious' if it requires hospitalization, is life-threatening or deadly
Stat News reported that the individual is expected to recover, but little else is known about their identity
It is not clear if regulators, AstraZeneca or Oxford called for the trial hold
The shot was dubbed the best hope for a vaccine by the WHO and is one of nine in phase three trials - the last tests before approval can be sought

Oxford and AstraZeneca's COVID-19 vaccine trials put on a hold after a UK participant had a 'serious' suspected reaction to the leading shot candidate